MedTrace Logo

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

NCT04808752 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-04-22

No results posted yet for this study

Summary

This is a prospective, open-label, multi-center, single-arm clinical trial

Conditions

Interventions

DRUG

Almonertinib

Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Qin Li Lu · Zhejiang Provincial People's Hospital，Hangzhou, China

  • Jun Chen · Ningbo Yinzhou People's Hospital，Ningbo, China

  • Ping Yu Li · The First Affiliated Hospital of Wenzhou Medical University，Wenzhou，China

  • Fei J Zhu · Taizhou Central Hospital，Taizhou，China

  • Bin Wang · Huzhou Central Hospital，Taizhou，China

  • Wu G Wu · Meizhou People's Hospital，Meizhou，China

  • Rong R Zhou · Xiangya Hospital of Central South University，Changsha，China

  • Yan X Lin · Union Hospital Affiliated to Fujian Medical University，Fujian，China

  • Yan Yu · Heilongjiang Cancer Hospital，Heilongjiang，China

  • Jun G Zhang · The First Affiliated Hospital of Zhengzhou University，Zhengzhou,China

  • Qiu Y Zhao · Henan Cancer Hospital，Henan，China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-09
Primary Completion
2024-06-15
Completion
2024-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04808752 on ClinicalTrials.gov